SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

Progenics Pharmaceuticals Q1 EPS $(0.190) Beats $(0.220) Estimate, Sales $6.200M Miss $7.900M Estimate

Progenics Pharmaceuticals (NASDAQ:PGNX) reported quarterly losses of $(0.190) per share which beat the analyst consensus estimate of $(0.220) by 13.64 percent. This is a 13.64 percent increase over losses of $(0.220) per

Benzinga · 05/07/2020 12:16

Progenics Pharmaceuticals (NASDAQ:PGNX) reported quarterly losses of $(0.190) per share which beat the analyst consensus estimate of $(0.220) by 13.64 percent. This is a 13.64 percent increase over losses of $(0.220) per share from the same period last year. The company reported quarterly sales of $6.200 million which missed the analyst consensus estimate of $7.900 million by 21.52 percent. This is a 44.83 percent increase over sales of $4.281 million the same period last year.